Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Incyte (INCY – Research Report) today. The company’s shares closed last Friday at $51.68.
Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Incyte, and Keros Therapeutics. According to TipRanks, Devarakonda has an average return of 14.9% and a 49.30% success rate on recommended stocks.
In addition to Truist Financial, Incyte also received a Buy from Piper Sandler’s Allison Bratzel in a report issued on April 26. However, on April 24, BMO Capital reiterated a Hold rating on Incyte (NASDAQ: INCY).
INCY market cap is currently $11.6B and has a P/E ratio of 19.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte (INCY) Company Description:
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
